Literature DB >> 33732669

Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy.

Shih-Hsing Lo1, Yi-Ching Liu1, Zen-Kong Dai1,2, I-Chen Chen1,2, Yen-Hsien Wu1, Jong-Hau Hsu1,2.   

Abstract

Valsartan/sacubitril is a new agent approved for the treatment of chronic heart failure in adults, with a combination of angiotensin receptor inhibitor and neprilysin inhibitor. However, the benefit of valsartan/sacubitril in pediatric patients is unknown. We herein report its clinical benefit in a case of acute decompensated heart failure in chemotherapy-induced cardiomyopathy. This case suggests that in children with acute heart failure refractory to conventional medications, low dose of sacubitril/valsartan may be an effective therapy.
Copyright © 2021 Lo, Liu, Dai, Chen, Wu and Hsu.

Entities:  

Keywords:  cardiomyopathy; chemotherapy; pediatric heart failure; treatment; valsartan/sacubitril

Year:  2021        PMID： 33732669      PMCID： PMC7959725          DOI： 10.3389/fped.2021.639551

Source DB:  PubMed          Journal:  Front Pediatr        ISSN： 2296-2360            Impact factor:   3.418


  10 in total

1.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Am Coll Cardiol       Date:  2017-04-28       Impact factor: 24.094

2.  Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).

Authors:  Robert Shaddy; Charles Canter; Nancy Halnon; Lazaros Kochilas; Joseph Rossano; Damien Bonnet; Christopher Bush; Ziqiang Zhao; Paul Kantor; Michael Burch; Fabian Chen
Journal:  Am Heart J       Date:  2017-07-17       Impact factor: 4.749

3.  In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization : A retrospective cohort study.

Authors:  R De Vecchis; C Ariano; G Di Biase; M Noutsias
Journal:  Herz       Date:  2018-03-08       Impact factor: 1.443

4.  Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.

Authors:  Jingwen Hu; Yucheng Wu; Xiujuan Zhou; Xiaozhi Wang; Wanying Jiang; Junyu Huo; Qijun Shan
Journal:  J Cardiovasc Pharmacol       Date:  2020-10       Impact factor: 3.105

5.  Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study.

Authors:  Joseph W Rossano; Jeffrey J Kim; Jamie A Decker; Jack F Price; Farhan Zafar; Daniel E Graves; David L S Morales; Jeffrey S Heinle; Biykem Bozkurt; Jeffrey A Towbin; Susan W Denfield; William J Dreyer; John L Jefferies
Journal:  J Card Fail       Date:  2012-04-10       Impact factor: 5.712

Review 6.  The pathophysiology of heart failure.

Authors:  Clinton D Kemp; John V Conte
Journal:  Cardiovasc Pathol       Date:  2012-01-05       Impact factor: 2.185

7.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

8.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

Review 9.  Current State of Pediatric Heart Failure.

Authors:  Bibhuti B Das
Journal:  Children (Basel)       Date:  2018-06-28

Review 10.  The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.

Authors:  Massimo Volpe; Marino Carnovali; Vittoria Mastromarino
Journal:  Clin Sci (Lond)       Date:  2016-01       Impact factor: 6.124
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.